Structure Therapeutics Inc. jumped to a record high Friday after new data on its oral weight-loss drug fueled expectations that the San Francisco-based company is closing the gap with larger competitors such as Pfizer Inc.
(Bloomberg) — One of the most-profitable trades across emerging markets this year is quickly losing its appeal.
Russia plans to reduce diesel exports from its key western ports to almost nothing next month after the government banned overseas sales to tame surging prices at home.
Better, smarter robots are leading a new industrial boom in the city of angels.
The Washington, DC region is bracing for disruption to the local economy when federal funding lapses at midnight on Sept. 30, forcing a US government shutdown.
The European Central Bank’s current level of interest rates is appropriate as policymakers are increasingly confident inflation will return to the target of 2%, Governing Council member Francois Villeroy de Galhau said.
The Fed-induced selloff in technology stocks has traders dusting off their turmoil playbooks. Trouble is, one of the most popular strategies isn’t working: hiding out in Apple Inc.
A senior Google executive once likened the company’s search advertising business to selling drugs, calling it “one of the world’s greatest business models ever created” since the company can “ignore” users and focus on generating revenue from advertising.
If Coca-Cola Co. has its way, winning college sports coaches will be doused with Powerade rather than Gatorade.
The Canadian economy rebounded slightly last month but still saw little growth, backing a case for the central bank to keep rates on hold despite inflation remaining elevated.
